Benge et al. studied the impact of KRAS and TP53 mutations on outcomes after first-line systemic therapy in patients with metastatic or recurrent NSCLC with STK11 gene mutations [48]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.